Status:
COMPLETED
Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial
Lead Sponsor:
Virginia Commonwealth University
Conditions:
Atrial Fibrillation and Flutter
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The primary objective of this study is to compare the incidence of rate control (defined as: HR \<110 beats/min or conversion to sinus rhythm) at 2 hours after medication administration between oral i...
Detailed Description
Atrial fibrillation (AF), a supraventricular tachyarrhythmia, is the primary diagnosis for over 467,000 hospitalizations each year. Historically, there have been two approaches to managing AF in the e...
Eligibility Criteria
Inclusion
- \>/= 18 years old
- Atrial fibrillation or flutter on electrocardiogram
- Heart rate \>110 beats/min
- Systolic blood pressure \>/= 90 mmHg
Exclusion
- Limited English proficiency (LEP)
- Pregnant
- Prisoners
- Wolff Parkinson White syndrome
- Administration of electrical or chemical cardioversion before screening
- Administration of other antiarrhythmics for acute heart rate control (excluding adenosine)
- History of allergy or idiosyncratic reaction to diltiazem
- Unable to take oral medications
- Heart rate \<60 beats/min
Key Trial Info
Start Date :
June 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 21 2021
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT03472495
Start Date
June 1 2018
End Date
March 21 2021
Last Update
March 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia Commonwealth University
Richmond, Virginia, United States, 23298